Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SQLE | Q14534 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1191493 | 0.73 | TSHR (0.52) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL16024946 | 0.73 | — | — | |
| SCHEMBL15709505 | 0.71 | TSHR (0.54) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL7561754 | 0.71 | TSHR (0.45) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL1982504 | 0.70 | TSHR (0.48) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL16024955 | 0.69 | TSHR (0.40) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL16012097 | 0.69 | TSHR (0.40) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL11295324 | 0.69 | SQLE (0.56) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL10045740 | 0.67 | TSHR (0.50) | TSHRKMT2ASQLEALOX15MEN1 | |
| SCHEMBL20633519 | 0.67 | TSHR (0.50) | TSHRKMT2ASQLEALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009747-A1 | PLATINUM METALLACYCLES COMPRISING N, P, OR AS RINGATOMS AND THEIR USE AS CATALYSTS IN 1,2-HYDROSILYLATION REACTIONS OF DIENES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009747-A1 | PLATINUM METALLACYCLES COMPRISING N, P, OR AS RINGATOMS AND THEIR USE AS CATALYSTS IN 1,2-HYDROSILYLATION REACTIONS OF DIENES | DHPS, APEX1, POP1 | TSHR 4166/4885KMT2A 2307/4885SQLE 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.